One Equity Partners : Case Study 2 - Global Opportunities




	CASE STUDY Global Opportunities in the Pharmaceutical Industry OEP believes the pharmaceutical industry will experience unprecedented changes in the next decade. While the industry benefits from an aging customer base, it faces tremendous pricing pressure and significant challenges in new product development. These trends present a clear opportunity for outsourced service providers who can reduce the time and cost of product development. Furthermore, interface with doctors and consumers will be critical to success. Consequently, sales forces and product distributors to specialist doctors for specific therapeutic categories will be attractive strategic assets. Beginning in 2001, OEP researched and called on companies providing outsourced product development, manufacturing and commercialization services to the pharmaceutical industry. As a result, OEP acquired Quintiles Transnational Corp. Quintiles Transnational Corp. (“Quintiles”), is the global market leader in outsourced product development and commercialization services to pharmaceutical and biotech companies. OEP believes the Company will benefit from the trends affecting the pharmaceutical industry. OEP purchased Quintiles in September 2003, and sold it in January 2008, for a gross IRR of 75%.	CASE STUDY Global Chemical Industry CASE STUDY Global Pharmaceutical Industry Return to Investment Approach
HOME TERMS OF USE SITE MAP SEARCH © 2005 ONE EQUITY PARTNERS

CASE STUDY
Global Opportunities in the Pharmaceutical Industry
OEP believes the pharmaceutical industry will experience unprecedented changes in the next decade. While the industry benefits from an aging customer base, it faces tremendous pricing pressure and significant challenges in new product development. These trends present a clear opportunity for outsourced service providers who can reduce the time and cost of product development. Furthermore, interface with doctors and consumers will be critical to success. Consequently, sales forces and product distributors to specialist doctors for specific therapeutic categories will be attractive strategic assets.

Beginning in 2001, OEP researched and called on companies providing outsourced product development, manufacturing and commercialization services to the pharmaceutical industry. As a result, OEP acquired Quintiles Transnational Corp.

Quintiles Transnational Corp. (“Quintiles”), is the global market leader in outsourced product development and commercialization services to pharmaceutical and biotech companies.

OEP believes the Company will benefit from the trends affecting the pharmaceutical industry.

OEP purchased Quintiles in September 2003, and sold it in January 2008, for a gross IRR of 75%.